$8.40
8.65%
Nasdaq, Aug 15, 03:30 pm CET
ISIN
US87167T2015
Symbol
SNPX

Synaptogenix Inc Stock price

$8.40
-1.30 13.36% 1M
+5.39 179.06% 6M
+4.93 142.07% YTD
+4.68 125.81% 1Y
-204.60 96.06% 3Y
-77.60 90.23% 5Y
-77.60 90.23% 10Y
-77.60 90.23% 20Y
Nasdaq, Closing price Fri, Aug 15 2025
-0.80 8.65%
ISIN
US87167T2015
Symbol
SNPX

Key metrics

Basic
Market capitalization
-
Enterprise Value
-
Net debt
positive
Cash
$14.8m
Shares outstanding
1.4m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
-
P/B
-
Financial Health
Equity Ratio
38.2%
Return on Equity
-200.1%
ROCE
-60.5%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-9.1m | -
EBIT
$-9.1m | $-13.4m
Net Income
$-13.0m | $-12.1m
Free Cash Flow
$-5.1m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-29.1% | -
EBIT
-29.2% | -97.3%
Net Income
-6.1% | 10.7%
Free Cash Flow
4.9%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-9.4
FCF per Share
$-3.6
Short interest
12.4%
Employees
4
Rev per Employee
$0.0
Show more

Is Synaptogenix Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,018 stocks worldwide.

Financial data from Synaptogenix Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 5.14 5.14
4% 4%
-
- Research and Development Expense 1.05 1.05
39% 39%
-
-9.14 -9.14
29% 29%
-
- Depreciation and Amortization 0.01 0.01
0% 0%
-
EBIT (Operating Income) EBIT -9.15 -9.15
29% 29%
-
Net Profit -13 -13
6% 6%
-

In millions USD.

Don't miss a Thing! We will send you all news about Synaptogenix Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Synaptogenix Inc Stock News

Neutral
PRNewsWire
about 2 months ago
New name and stock symbol highlight strategic commitment to TAO, the leading AI cryptocurrency NEW YORK , July 1, 2025 /PRNewswire/ -- TAO Synergies Inc. (Nasdaq: TAOX) (the "Company"), formerly Synaptogenix, Inc. (Nasdaq: SNPX), announces that its common stock, listed on the Nasdaq Capital Market, begins trading under the new ticker symbol, "TAOX," effective at the market open today, July 1, 2...
Neutral
PRNewsWire
about 2 months ago
New trading symbol "TAOX" effective Tuesday, July 1, 2025, New name represents Company's strategic focus on the synergies between cryptocurrency and AI NEW YORK , June 26, 2025 /PRNewswire/ -- TAO Synergies Inc. (the "Company"), formerly Synaptogenix, Inc. (NASDAQ: SNPX), today announced that it will begin trading on Nasdaq under the new ticker symbol "TAOX" on Tuesday, July 1, 2025, in accorda...
Neutral
PRNewsWire
about 2 months ago
Strategic capital deployment into TAO advances Synaptogenix's blockchain treasury model, leveraging BitGo's custody, trading and staking capabilities to generate token-based yield NEW YORK , June 24, 2025 /PRNewswire/ -- Synaptogenix (NASDAQ: SNPX) today announced its initial purchase of TAO as part of the Company's recently announced cryptocurrency treasury strategy focused exclusively on arti...
More Synaptogenix Inc News

Company Profile

Synaptogenix, Inc. operates as a biopharmaceutical company. It develops a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer’s disease, which is in the clinical testing stage. The firm also evaluates potential therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions. The company was founded on October 31, 2012 and is headquartered in New York, NY.

Head office United States
CEO Alan Tuchman
Employees 4
Founded 2012
Website www.synaptogen.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today